The first 2 authors contributed equally to this study.
C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality
A European study of 313 patients
Article first published online: 18 JUL 2007
Copyright © 2007 American Cancer Society
Volume 110, Issue 6, pages 1241–1247, 15 September 2007
How to Cite
Karakiewicz, P. I., Hutterer, G. C., Trinh, Q.-D., Jeldres, C., Perrotte, P., Gallina, A., Tostain, J. and Patard, J.-J. (2007), C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality. Cancer, 110: 1241–1247. doi: 10.1002/cncr.22896
- Issue published online: 31 AUG 2007
- Article first published online: 18 JUL 2007
- Manuscript Accepted: 26 APR 2007
- Manuscript Revised: 23 APR 2007
- Manuscript Received: 9 MAR 2007
- University of Montreal Health Center Urology Associates
- Quebec Foundation for Health Research (FRSQ)
- University of Montreal Department of Surgery
- University of Montreal Health Center (CHUM) Foundation to (P.I.K.)
- C-reactive protein;
- renal cell carcinoma
C-reactive protein (CRP) represents a promising prognostic variable in patients with sporadic renal cell carcinoma (RCC). It was hypothesized that CRP can improve the prognostic ability of standard RCC-specific mortality (RCC-SM) predictors in patients treated with nephrectomy for all stages of RCC.
Radical nephrectomy was performed in 314 patients from 2 European centers. Life table, Kaplan-Meier, and Cox regression analyses addressed RCC-SM. Covariates included age, gender, TNM stage, tumor size, Fuhrman grade, and histologic subtype.
The median survival of the cohort was 19.9 years. Age ranged from 10 to 77 years. Most patients were male (69%). T-stages were distributed as follows: T1-121 (38.7%), T2-45 (14.4%), T3-140 (44.7%), T4-7 (2.2%). CRP values ranged from 1.0 to 358.0 mg/L (mean 40.9, median 11.0 mg/L). In multivariable analyses, CRP was an independent predictor of RCC-SM (P = .003). The consideration of CRP in the multivariable model increased the predictive accuracy by 3.7% (P < .001). Moreover, the model with CRP performed 2.4% and 4.6% better than the UCLA Integrated Staging System (UISS) at, respectively, 2 and 5 years.
CRP represents an informative predictor of RCC-SM. Its routine use could allow better risk stratification and risk-adjusted follow-up of RCC patients. Cancer 2007. © 2007 American Cancer Society.